In Combo Studies for the Optimization of 5-Aminoanthranilic Acid Derivatives as Potential Multitarget Drugs for the Management of Metabolic Syndrome

Metabolic syndrome is a set of risk factors that consist of abdominal obesity, arterial hypertension, alterations in the lipid profile, and hyperglycemia. The current therapeutic strategy includes polypharmacy, using three or more drugs to control each syndrome component. However, this approach has drawbacks that could lead to therapeutic failure. Multitarget drugs are molecules with the ability to act on different targets simultaneously and are an attractive alternative for treating complex diseases such as metabolic syndrome. Previously, we identified a triamide derivative of 5-aminoanthranilic acid that exhibited hypoglycemic, hypolipemic, and antihypertensive activities simultaneously. In the present study, we report the synthesis and in combo evaluation of new derivatives of anthranilic acid, intending to identify the primary structural factors that improve the activity over metabolic syndrome-related parameters. We found that substitution on position 5, incorporation of 3,4-dimethoxyphenyl substituents, and having a free carboxylic acid group lead to the in vitro inhibition of HMG-CoA reductase, and simultaneously the diminution of the serum levels of glucose, triglycerides, and cholesterol in a diet-induced in vivo model.

[1]  A. M. Inarejos-García,et al.  Supplementation with Two New Standardized Tea Extracts Prevents the Development of Hypertension in Mice with Metabolic Syndrome , 2022, Antioxidants.

[2]  G. Albadrani,et al.  The Role of Myrrh Metabolites in Cancer, Inflammation, and Wound Healing: Prospects for a Multi-Targeted Drug Therapy , 2022, Pharmaceuticals.

[3]  S. Sestito,et al.  Design, Synthesis, and In Vitro Evaluation of Novel 8-Amino-Quinoline Combined with Natural Antioxidant Acids , 2022, Pharmaceuticals.

[4]  A. Stringaro,et al.  Design, Synthesis, and In Vitro, In Silico and In Cellulo Evaluation of New Pyrimidine and Pyridine Amide and Carbamate Derivatives as Multi-Functional Cholinesterase Inhibitors , 2022, Pharmaceuticals.

[5]  N. Subbarao,et al.  Discovery of multi-target mur enzymes inhibitors with anti-mycobacterial activity through a Scaffold approach , 2022, Journal of biomolecular structure & dynamics.

[6]  K. Ma,et al.  Bezafibrate Exerts Neuroprotective Effects in a Rat Model of Sporadic Alzheimer’s Disease , 2022, Pharmaceuticals.

[7]  G. Navarrete-Vázquez,et al.  Synthesis, In Vitro, In Vivo and In Silico Antidiabetic Bioassays of 4-Nitro(thio)phenoxyisobutyric Acids Acting as Unexpected PPARγ Modulators: An In Combo Study , 2022, Pharmaceuticals.

[8]  H. Assi,et al.  Metabolic Syndrome: Updates on Pathophysiology and Management in 2021 , 2022, International journal of molecular sciences.

[9]  A. Muth,et al.  Polypharmacology: The Science of Multi-targeting Molecules. , 2022, Pharmacological research.

[10]  C. Cervellati,et al.  Prognostic Role of Metabolic Syndrome in COVID-19 Patients: A Systematic Review Meta-Analysis , 2021, Viruses.

[11]  C. Yun,et al.  A Novel Statin Compound from Monacolin J Produced Using CYP102A1-Catalyzed Regioselective C-Hydroxylation , 2021, Pharmaceuticals.

[12]  C. Guerra-Araiza,et al.  In Silico-Based Design and In Vivo Evaluation of an Anthranilic Acid Derivative as a Multitarget Drug in a Diet-Induced Metabolic Syndrome Model , 2021, Pharmaceuticals.

[13]  A. Astrup,et al.  The triglyceride‐glucose index as an adiposity marker and a predictor of fat loss induced by a low‐calorie diet , 2021, European journal of clinical investigation.

[14]  R. Mercadillo,et al.  Nutritional Status Influences Oxidative Stress and Insulin Resistance in Preschool Children. , 2021, Metabolic syndrome and related disorders.

[15]  Marine Peuchmaur,et al.  β-Carboline as a Privileged Scaffold for Multitarget Strategies in Alzheimer's Disease Therapy. , 2021, Journal of medicinal chemistry.

[16]  Kyungdo Han,et al.  The triglyceride glucose index is a simple and low-cost marker associated with atherosclerotic cardiovascular disease: a population-based study , 2020, BMC Medicine.

[17]  S. Müller,et al.  A triple farnesoid X receptor and peroxisome proliferator-activated receptor α/δ activator reverses hepatic fibrosis in diet-induced NASH in mice , 2020, Communications Chemistry.

[18]  M. Holeček,et al.  Effects of low and high doses of fenofibrate on protein, amino acid, and energy metabolism in rat , 2020, International journal of experimental pathology.

[19]  F. Hsiao,et al.  Combined Effects of Frailty and Polypharmacy on Health Outcomes in Older Adults: Frailty Outweighs Polypharmacy. , 2020, Journal of the American Medical Directors Association.

[20]  F. J. Luque,et al.  Centrally Active Multitarget Anti-Alzheimer Agents Derived from the Antioxidant Lead CR-6. , 2020, Journal of medicinal chemistry.

[21]  R. Muniyappa,et al.  Metabolic Syndrome and COVID 19: Endocrine-Immune-Vascular Interactions Shapes Clinical Course , 2020, Endocrinology.

[22]  C. Espinosa-Garcia,et al.  Sex differences in the performance of cognitive tasks in a murine model of metabolic syndrome , 2020, The European journal of neuroscience.

[23]  M. Rarey,et al.  ProteinsPlus: interactive analysis of protein–ligand binding interfaces , 2020, Nucleic Acids Res..

[24]  Juan Francisco Sánchez-Tejeda,et al.  A Definition of “Multitargeticity”: Identifying Potential Multitarget and Selective Ligands Through a Vector Analysis , 2020, Frontiers in Chemistry.

[25]  A. Sureda,et al.  Metabolic Syndrome Is Associated with Oxidative Stress and Proinflammatory State , 2020, Antioxidants.

[26]  B. Hanratty,et al.  Adverse Outcomes of Polypharmacy in Older People: Systematic Review of Reviews. , 2020, Journal of the American Medical Directors Association.

[27]  S. Yamashita,et al.  Pemafibrate, a New Selective PPARα Modulator: Drug Concept and Its Clinical Applications for Dyslipidemia and Metabolic Diseases , 2020, Current Atherosclerosis Reports.

[28]  C. Supuran,et al.  New anthranilic acid-incorporating N-benzenesulfonamidophthalimides as potent inhibitors of carbonic anhydrases I, II, IX, and XII: Synthesis, in vitro testing, and in silico assessment. , 2019, European journal of medicinal chemistry.

[29]  A. Ammazzalorso,et al.  Multitarget PPARγ agonists as innovative modulators of the metabolic syndrome. , 2019, European journal of medicinal chemistry.

[30]  Peter W. Kenny,et al.  The nature of ligand efficiency , 2018, Journal of Cheminformatics.

[31]  D. Hadjipavlou-Litina,et al.  Cinnamate Hybrids: A Unique Family of Compounds with Multiple Biological Activities. , 2019, Current pharmaceutical biotechnology.

[32]  Shaodong Guo,et al.  Etiology of Metabolic Syndrome and Dietary Intervention , 2018, International journal of molecular sciences.

[33]  Juan Francisco Sánchez-Tejeda,et al.  In Silico Studies on Compounds Derived from Calceolaria: Phenylethanoid Glycosides as Potential Multitarget Inhibitors for the Development of Pesticides , 2018, Biomolecules.

[34]  Fernanda I. Saldívar-González,et al.  Inhibitors of DNA Methyltransferases From Natural Sources: A Computational Perspective , 2018, Front. Pharmacol..

[35]  A. Vega‐Gálvez,et al.  Evaluation of phenolic profiles and antioxidant capacity of maqui (Aristotelia chilensis) berries and their relationships to drying methods. , 2018, Journal of the science of food and agriculture.

[36]  S. Tuntipopipat,et al.  Ferulic Acid Supplementation Improves Lipid Profiles, Oxidative Stress, and Inflammatory Status in Hyperlipidemic Subjects: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial , 2018, Nutrients.

[37]  V. Sládek,et al.  Molecular association model of PPARα and its new specific and efficient ligand, pemafibrate: Structural basis for SPPARMα. , 2018, Biochemical and biophysical research communications.

[38]  Tariq M. Alhawassi,et al.  Polypharmacy among patients with diabetes: a cross-sectional retrospective study in a tertiary hospital in Saudi Arabia , 2018, BMJ Open.

[39]  P. Paoli,et al.  Ursolic acid derivatives as potential antidiabetic agents: In vitro, in vivo, and in silico studies , 2018, Drug development research.

[40]  M. Saklayen.  The Global Epidemic of the Metabolic Syndrome , 2018, Current Hypertension Reports.

[41]  E. Hernández-Núñez,et al.  Design, Synthesis and in Combo Antidiabetic Bioevaluation of Multitarget Phenylpropanoic Acids † , 2018, Molecules.

[42]  Rona R. Ramsay,et al.  A perspective on multi-target drug discovery and design for complex diseases , 2018, Clinical and Translational Medicine.

[43]  S. Sreenivasan,et al.  Pathophysiology of the metabolic syndrome. , 2018, Clinics in dermatology.

[44]  Y. Im,et al.  Structures of PPARγ complexed with lobeglitazone and pioglitazone reveal key determinants for the recognition of antidiabetic drugs , 2017, Scientific Reports.

[45]  N. Karp,et al.  A high-throughput in vivo screening method in the mouse for identifying regulators of metastatic colonization , 2017, Nature Protocols.

[46]  Gillian E. Caughey,et al.  What is polypharmacy? A systematic review of definitions , 2017, BMC Geriatrics.

[47]  Gerd Geisslinger,et al.  A Dual Modulator of Farnesoid X Receptor and Soluble Epoxide Hydrolase To Counter Nonalcoholic Steatohepatitis. , 2017, Journal of medicinal chemistry.

[48]  N. Mishra,et al.  Synthesis and anti-inflammatory evaluation of N-sulfonyl anthranilic acids via Ir(III)-catalyzed C-H amidation of benzoic acids. , 2017, Bioorganic & medicinal chemistry letters.

[49]  Weilin Zhang,et al.  Computational Multitarget Drug Design , 2017, J. Chem. Inf. Model..

[50]  A. Cavalli,et al.  Multitarget Drug Discovery and Polypharmacology , 2016, ChemMedChem.

[51]  J. Martínez,et al.  Triglyceride-glucose index (TyG index) in comparison with fasting plasma glucose improved diabetes prediction in patients with normal fasting glucose: The Vascular-Metabolic CUN cohort. , 2016, Preventive medicine.

[52]  S. Grundy.  Metabolic syndrome update. , 2016, Trends in cardiovascular medicine.

[53]  A. Cavalli,et al.  Navigating the Chemical Space of Multitarget-Directed Ligands: From Hybrids to Fragments in Alzheimer’s Disease , 2016, Molecules.

[54]  L. Rabelo,et al.  Aging Increases Susceptibility to High Fat Diet-Induced Metabolic Syndrome in C57BL/6 Mice: Improvement in Glycemic and Lipid Profile after Antioxidant Therapy , 2016, Oxidative medicine and cellular longevity.

[55]  Antonio Lavecchia,et al.  In silico methods to address polypharmacology: current status, applications and future perspectives. , 2016, Drug discovery today.

[56]  Juan Rodrigo Salazar,et al.  Sterols and triterpenoids as potential anti-inflammatories: Molecular docking studies for binding to some enzymes involved in inflammatory pathways. , 2015, Journal of molecular graphics & modelling.

[57]  S. Masuda,et al.  Identification of a New Type of Covalent PPARγ Agonist using a Ligand-Linking Strategy. , 2015, ACS chemical biology.

[58]  Alan Talevi,et al.  Multi-target pharmacology: possibilities and limitations of the “skeleton key approach” from a medicinal chemist perspective , 2015, Front. Pharmacol..

[59]  S. Greenwald,et al.  Ferulic Acid Alleviates Changes in a Rat Model of Metabolic Syndrome Induced by High-Carbohydrate, High-Fat Diet , 2015, Nutrients.

[60]  Douglas E. V. Pires,et al.  pkCSM: Predicting Small-Molecule Pharmacokinetic and Toxicity Properties Using Graph-Based Signatures , 2015, Journal of medicinal chemistry.

[61]  M. Schubert-Zsilavecz,et al.  Anthranilic acid derivatives as nuclear receptor modulators--development of novel PPAR selective and dual PPAR/FXR ligands. , 2015, Bioorganic & medicinal chemistry.

[62]  Oliver Werz,et al.  Multi-target approach for natural products in inflammation. , 2014, Drug discovery today.

[63]  Aarón Mendieta,et al.  Synthesis and highly potent hypolipidemic activity of alpha-asarone- and fibrate-based 2-acyl and 2-alkyl phenols as HMG-CoA reductase inhibitors. , 2014, Bioorganic & medicinal chemistry.

[64]  Xuefeng Yu,et al.  O R I G I N a L I N V E S T I G a T I O N Open Access , 2022 .

[65]  B. Ma,et al.  Metabolomic analysis of simvastatin and fenofibrate intervention in high-lipid diet-induced hyperlipidemia rats , 2014, Acta Pharmacologica Sinica.

[66]  A. Kourounakis,et al.  Multi-target drug design approaches for multifactorial diseases: from neurodegenerative to cardiovascular applications. , 2014, Current medicinal chemistry.

[67]  Hyung-Sik Kang,et al.  Chimeric cytochromes P450 engineered by domain swapping and random mutagenesis for producing human metabolites of drugs , 2014, Biotechnology and bioengineering.

[68]  G. Schneider,et al.  Anthranilic acid derivatives as novel ligands for farnesoid X receptor (FXR). , 2014, Bioorganic & medicinal chemistry.

[69]  J. Medina-Franco,et al.  Synthesis of 2-{2-[(α/β-naphthalen-1-ylsulfonyl)amino]-1,3-thiazol-4-yl} acetamides with 11β-hydroxysteroid dehydrogenase inhibition and in combo antidiabetic activities. , 2014, European journal of medicinal chemistry.

[70]  M. Youdim,et al.  From Single Target to Multitarget/Network Therapeutics in Alzheimer’s Therapy , 2014, Pharmaceuticals.

[71]  Hai-bin Luo,et al.  Design, synthesis, and evaluation of multitarget-directed resveratrol derivatives for the treatment of Alzheimer's disease. , 2013, Journal of medicinal chemistry.

[72]  J. Medina-Franco,et al.  Discovery, synthesis and in combo studies of a tetrazole analogue of clofibric acid as a potent hypoglycemic agent. , 2013, Bioorganic & medicinal chemistry letters.

[73]  H. Roche,et al.  Oxidative stress is associated with the number of components of metabolic syndrome: LIPGENE study , 2013, Experimental & Molecular Medicine.

[74]  Alejandro Speck-Planche,et al.  Fragment-based approach for the in silico discovery of multi-target insecticides , 2012 .

[75]  A. Oladejo,et al.  OVERVIEW OF THE METABOLIC SYNDROME; AN EMERGING PANDEMIC OF PUBLIC HEALTH SIGNIFICANCE , 2011, Annals of Ibadan postgraduate medicine.

[76]  Alejandro Speck-Planche,et al.  Current computational approaches towards the rational design of new insecticidal agents. , 2011, Current computer-aided drug design.

[77]  L. Brown,et al.  Rodent Models for Metabolic Syndrome Research , 2010, Journal of biomedicine & biotechnology.

[78]  C. Thiemermann,et al.  Pioglitazone improves lipid and insulin levels in overweight rats on a high cholesterol and fructose diet by decreasing hepatic inflammation , 2010, British journal of pharmacology.

[79]  J. Imig,et al.  Simvastatin and Tempol Protect Against Endothelial Dysfunction and Renal Injury in a Model of Obesity and Hypertension , 2008, American journal of physiology. Renal physiology.

[80]  R. Apak,et al.  Cupric ion reducing antioxidant capacity assay for antioxidants in human serum and for hydroxyl radical scavengers. , 2010, Methods in molecular biology.

[81]  D. Armstrong.  Advanced Protocols in Oxidative Stress II , 2010, Methods in Molecular Biology.

[82]  Craig K. Abbey,et al.  High-throughput in vivo screening of targeted molecular imaging agents , 2009, Proceedings of the National Academy of Sciences.

[83]  M. Rodríguez-Moran,et al.  The product of fasting glucose and triglycerides as surrogate for identifying insulin resistance in apparently healthy subjects. , 2008, Metabolic syndrome and related disorders.

[84]  Ardiansyah,et al.  Novel effects of a single administration of ferulic acid on the regulation of blood pressure and the hepatic lipid metabolic profile in stroke-prone spontaneously hypertensive rats. , 2008, Journal of agricultural and food chemistry.

[85]  T. Dusek,et al.  Pathophysiology of Metabolic Syndrome , 2007, EJIFCC.

[86]  S. Grundy.  Drug therapy of the metabolic syndrome: minimizing the emerging crisis in polypharmacy , 2006, Nature Reviews Drug Discovery.

[87]  Richard Kahn,et al.  The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. , 2005, Diabetes care.

[88]  R. Kahn,et al.  The metabolic syndrome: time for a critical appraisal , 2005, Diabetologia.

[89]  Péter Csermely,et al.  The efficiency of multi-target drugs: the network approach might help drug design. , 2004, Trends in pharmacological sciences.

[90]  S. Grundy.  Metabolic syndrome: therapeutic considerations. , 2005, Handbook of experimental pharmacology.

[91]  C. Wong,et al.  Alpha-asarone inhibits HMG-CoA reductase, lowers serum LDL-cholesterol levels and reduces biliary CSI in hypercholesterolemic rats. , 2003, Phytomedicine : international journal of phytotherapy and phytopharmacology.

[92]  F. Leighton,et al.  Juice and phenolic fractions of the berry Aristotelia chilensis inhibit LDL oxidation in vitro and protect human endothelial cells against oxidative stress. , 2002, Journal of agricultural and food chemistry.

[93]  F. C. Nelson,et al.  The discovery of anthranilic acid-based MMP inhibitors. Part 2: SAR of the 5-position and P1(1) groups. , 2001, Bioorganic & medicinal chemistry letters.

[94]  R. Buckingham,et al.  Therapeutic index for rosiglitazone in dietary obese rats: separation of efficacy and haemodilution , 1999, British journal of pharmacology.